We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.
- Authors
Foran, J M; Rohatiner, A Z; Cunningham, D; Popescu, R A; Solal-Celigny, P; Ghielmini, M; Coiffier, B; Johnson, P W; Gisselbrecht, C; Reyes, F; Radford, J A; Bessell, E M; Souleau, B; Benzohra, A; Lister, T A
- Abstract
Mantle-cell lymphoma (MCL), immunocytoma (IMC), and small B-cell lymphocytic lymphoma (SLL) are B-cell malignancies that express CD20 and are incurable with standard therapy. A multicenter phase II study was conducted to assess the toxicity and the overall response rates (RR) and complete response (CR) rates to rituximab (chimeric anti-CD20 monoclonal antibody).
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Vol 18, Issue 2, p317
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2000.18.2.317